Valuation Macro Group Pharmaceuticals (Macro Capital) S.A.E
Stocks
MCRO
EGS7D971C011
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.210 EGP | 0.00% |
|
-5.47% | +6.14% |
| 05-17 | Macro Group Pharmaceutical Q1 consol profit egp 33.3 million | RE |
| 02-19 | Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: Macro Group Pharmaceuticals (Macro Capital) S.A.E
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Market Cap 1 | 1,870 | 1,682 | 1,323 | 650 |
| Change | - | -10.06% | -21.36% | -50.86% |
| Enterprise Value (EV) 1 | 1,887 | 1,833 | 1,577 | 807.4 |
| Change | - | -2.88% | -13.97% | -48.8% |
| P/E Ratio | 10.9x | -6.1x | -33.1x | 5.7x |
| PBR | 4.04x | 17.6x | 16.7x | 3.36x |
| PEG | 0.6x | 0x | 0.4x | -0x |
| Capitalization / Revenue | 2.56x | 3.2x | 2.54x | 0.73x |
| EV / Revenue | 2.59x | 3.48x | 3.03x | 0.9x |
| EV / EBITDA | 7.93x | -10.5x | 95x | 5.75x |
| EV / EBIT | 8.05x | -10x | 131x | 5.96x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Dividend per Share 2 | 0.1067 | - | - | - |
| Rate of return | 3.25% | - | - | - |
| EPS 2 | 0.3 | -0.4835 | -0.07 | 0.2 |
| Distribution rate | 35.6% | - | - | - |
| Net sales 1 | 729.6 | 526 | 520 | 894.5 |
| EBITDA 1 | 237.9 | -175.2 | 16.6 | 140.4 |
| EBIT 1 | 234.4 | -182.4 | 12.03 | 135.4 |
| Net income 1 | 173.8 | -272.7 | -38.1 | 115.7 |
| Net Debt 1 | 16.96 | 150.9 | 254 | 157.4 |
| Reference price 2 | 3.280 | 2.950 | 2.320 | 1.140 |
| Nbr of stocks (in thousands) | 570,206 | 570,206 | 570,206 | 570,206 |
| Announcement Date | 3/2/23 | 4/16/24 | 2/26/25 | 2/19/26 |
1EGP in Million2EGP
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 13.27M | |
| 33.15x | 12.05x | 24.81x | 0.6% | 1,010B | |
| 25.74x | 5.93x | 16.13x | 2.22% | 580B | |
| 27.88x | 6.79x | 13.86x | 3.01% | 402B | |
| 17.71x | 4.37x | 10.73x | 3.04% | 330B | |
| 21.24x | 5.49x | 13.32x | 2.92% | 281B | |
| 22.78x | 4.74x | 13.47x | 1.85% | 280B | |
| 12.7x | 4.76x | 9.73x | 3.95% | 197B | |
| 23.09x | 6.16x | 10.76x | 2.84% | 192B | |
| -45x | 5.43x | 29.95x | 2.58% | 156B | |
| Average | 15.48x | 6.19x | 15.86x | 2.56% | 342.89B | |
| Weighted average by Cap. | 22.68x | 7.47x | 17.41x | 2.09% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MCRO Stock
- Valuation Macro Group Pharmaceuticals (Macro Capital) S.A.E
Select your edition
All financial news and data tailored to specific country editions
